Difference between revisions of "Lenalidomide (Revlimid)"
Jump to navigation
Jump to search
(Created page with "==General information== Class/mechanism: <ref name="insert">[http://www.revlimid.com/pdf/REVLIMID_PI.pdf Lenalidomide (Revlimid) package insert]</ref><ref>[http://hemonc.org/docs...") |
|||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: <ref name="insert">[http://www.revlimid.com/pdf/REVLIMID_PI.pdf Lenalidomide (Revlimid) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/lenalidomide.pdf Lenalidomide (Revlimid) package insert (locally hosted backup)]</ref> | + | Class/mechanism: Second-generation immunomodulatory drug (IMiD) similar to [[Thalidomide (Thalomid)]]; mechanism not fully understood. Lenalidomide's mechanism may involve immunomodulatory, antiinflammatory, and antiangiogenic effects and suppression of tumor necrosis factor-alpha (TNF-α) from peripheral blood mononuclear cells. It has been observed to inhibit cells with the 5q deletion in myelodysplastic syndromes. It has also been seen in vitro to inhibit cyclooxygenase-2 (COX-2) expression, but not COX-1.<ref name="insert">[http://www.revlimid.com/pdf/REVLIMID_PI.pdf Lenalidomide (Revlimid) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/lenalidomide.pdf Lenalidomide (Revlimid) package insert (locally hosted backup)]</ref><ref>[http://revlimid.com/ Revlimid manufacturer's site]</ref><ref name="revassist">[http://revlimid.com/hcp/RevAssist.aspx RevAssist program]</ref> |
| − | <br>Route: | + | <br>Route: PO |
| − | <br>Extravasation: | + | <br>Extravasation: n/a |
| + | *Use of Lenalidomide (Revlimid) requires participation the [http://revlimid.com/hcp/RevAssist.aspx RevAssist program].<ref name="revassist"></ref> | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | ||
==Patient drug information== | ==Patient drug information== | ||
| + | *[http://revlimid.com/docs/Revlimid_Med_Guide.pdf Lenalidomide (Revlimid) patient medication guide]<ref>[http://revlimid.com/docs/Revlimid_Med_Guide.pdf Lenalidomide (Revlimid) patient medication guide]</ref> | ||
*[http://chemocare.com/bio/lenalidomide.asp Lenalidomide (Revlimid) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/lenalidomide.asp Lenalidomide (Revlimid) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/bio/lenalidomide.asp Lenalidomide (Revlimid) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/lenalidomide.asp Lenalidomide (Revlimid) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/lenalidomide-patient-drug-information Lenalidomide (Revlimid) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/lenalidomide-patient-drug-information Lenalidomide (Revlimid) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/lenalidomide-patient-drug-information Lenalidomide (Revlimid) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/lenalidomide-patient-drug-information Lenalidomide (Revlimid) patient drug information (UpToDate)]</ref> | ||
Revision as of 17:28, 22 February 2012
General information
Class/mechanism: Second-generation immunomodulatory drug (IMiD) similar to Thalidomide (Thalomid); mechanism not fully understood. Lenalidomide's mechanism may involve immunomodulatory, antiinflammatory, and antiangiogenic effects and suppression of tumor necrosis factor-alpha (TNF-α) from peripheral blood mononuclear cells. It has been observed to inhibit cells with the 5q deletion in myelodysplastic syndromes. It has also been seen in vitro to inhibit cyclooxygenase-2 (COX-2) expression, but not COX-1.[1][2][3][4]
Route: PO
Extravasation: n/a
- Use of Lenalidomide (Revlimid) requires participation the RevAssist program.[4]
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].
Patient drug information
- Lenalidomide (Revlimid) patient medication guide[5]
- Lenalidomide (Revlimid) patient drug information (Chemocare)[6]
- Lenalidomide (Revlimid) patient drug information (UpToDate)[7]
References
- ↑ 1.0 1.1 Lenalidomide (Revlimid) package insert
- ↑ Lenalidomide (Revlimid) package insert (locally hosted backup)
- ↑ Revlimid manufacturer's site
- ↑ 4.0 4.1 RevAssist program
- ↑ Lenalidomide (Revlimid) patient medication guide
- ↑ Lenalidomide (Revlimid) patient drug information (Chemocare)
- ↑ Lenalidomide (Revlimid) patient drug information (UpToDate)